In CNBC’s “Mad Money” lightning round, Cramer praised Arista Networks, Ross Stores and Astera Labs, preferred Eli Lilly over Hims & Hers Health, rejected Rigetti Computing and said he was unfamiliar with MakeMyTrip.
Jim Cramer offered a mixed set of rapid-fire stock views on CNBC’s “Mad Money,” endorsing Arista Networks, Ross Stores and Astera Labs while favoring Eli Lilly over Hims & Hers Health. He called Hims & Hers Health a “controversial stock” and said, “I really prefer to just own Eli Lilly,” later describing Eli Lilly as “classic own don't trade” and saying he has owned it for years and plans to continue because it is “a great business with great drugs.” Cramer said Astera Labs remained a buy because “nothing changed” and the weakness was “just a matter of sentiment,” while he said he did not care for Rigetti Computing and was not familiar with MakeMyTrip. He also said Arista is not entirely dependent on the data center and has “a lot of things going for it,” and praised Ross Stores as having improved from “good” to “terrific.”